Welcome to our dedicated page for Integrated Biopharma SEC filings (Ticker: INBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integrated BioPharma, Inc. filings document formal disclosures for a Delaware operating company whose public reports are tied to vitamins, nutritional supplements, herbal products and contract manufacturing. Recent Form 8-K filings furnish quarterly and fiscal-year results under Item 2.02, including press-release exhibits covering revenue, operating results and per-share data.
The filing record also includes material-event reports on credit-line arrangements and related-party lease matters involving the wholly owned subsidiary Manhattan Drug Company, as well as definitive proxy materials and annual meeting voting results covering director elections, executive-compensation votes, stockholder voting matters and governance procedures. Cover-page disclosures identify no securities registered on a national exchange under Section 12(b).
Integrated BioPharma, Inc. amended its loan agreement with PNC Bank, extending its existing committed revolving line of credit, which allows borrowings up to $4,000,000, to April 14, 2027. The company and its subsidiary also entered into a new $250,000 Convertible Line of Credit Note for equipment and vehicle purchases.
Before conversion, the new equipment line bears interest at a Daily Rate equal to one-month SOFR plus 250 basis points. The amendment also terminates a prior Convertible Equipment Line of Credit Note with a maximum amount of $500,000 that had matured and is no longer in effect.
INTEGRATED BIOPHARMA director Eric J. Friedman received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, giving him rights to purchase up to 50,000 shares once vested.
INTEGRATED BIOPHARMA INC director and 10% owner Damon DeSantis received a stock option grant covering 50,000 shares of common stock. The options carry an exercise price of $0.2000 per share and expire on June 24, 2036. Following this grant, DeSantis holds options for 50,000 shares directly. The award vests in four equal installments of 12,500 options on each of September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, meaning he can exercise portions of the grant over time as they vest.
INTEGRATED BIOPHARMA INC director Eric J. Friedman received a grant of stock options for 50,000 shares of Common Stock. These options have an exercise price of $0.1900 per share and expire on June 24, 2036. The grant is compensation-related rather than an open‑market purchase.
The options vest and become exercisable in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, aligning vesting with future service periods.
INTEGRATED BIOPHARMA director Robert Canarick received a grant of 50,000 stock options for common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options between September 2026 and June 2027.
Integrated BioPharma Inc. director William H. Milmoe received a grant of stock options to acquire 50,000 shares of Common Stock. The options have an exercise price of $0.19 per share and were awarded at no cost to him.
The options vest in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, and expire on June 24, 2036. This is a routine compensation-related award rather than an open-market trade.
Integrated BioPharma, Inc. reported weaker results for the quarter ended March 31, 2026, with revenue of $10.1 million versus $13.9 million a year earlier, a 27.3% decline. The company swung from operating income of about $0.7 million to an operating loss of about $1.1 million, and from net income of about $0.6 million to a net loss of about $0.8 million, or $(0.03) per diluted share.
For the nine months ended March 31, 2026, revenue was $34.1 million compared to $40.2 million, down 15.2%, with a net loss of about $1.5 million versus net income of about $1.0 million a year earlier. Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented about 90% of total revenue in the 2026 period, up from 83% in 2025, underscoring significant customer concentration.
Integrated BioPharma, Inc. reported weaker results for the quarter and nine months ended March 31, 2026, driven by lower volumes and margin pressure. Net sales for the nine-month period fell to $34,076 from $40,178, a 15.2% decline, with Contract Manufacturing and Other Business Lines both down.
The company swung to a nine‑month operating loss of $1,836 from operating income of $1,431, and posted a net loss of $1,476 versus prior‑year net income of $986. For the March quarter, sales declined 27.5% to $10,107, producing a gross loss and net loss of $837.
Customer concentration remains high: two Contract Manufacturing customers accounted for about 90% of consolidated net sales, led by Life Extension and Herbalife. Despite the downturn, cash improved to $5,826 and working capital was about $12,447, supported by an undrawn revolving credit facility of roughly $4,500. Management highlights inflation, tariffs and labor costs as ongoing margin headwinds.
Integrated BioPharma Inc. saw a long‑standing shareholder group led by the late Carl DeSantis, CD Financial, LLC and CDS Group Holdings, L.L.C. report that it no longer beneficially owns any common stock. The filing states the group’s holdings fell to 0 shares, or 0.0% of the class.
Following DeSantis’s death, all of the group’s shares were transferred on March 24, March 30 and April 15, 2026 to CDDS 2.0, LLC, a Florida company controlled by Damon DeSantis. As a result, CDDS 2.0, LLC directly, and Damon DeSantis indirectly, now beneficially own more than five percent of Integrated BioPharma’s common stock.
Integrated BioPharma Inc. received an updated ownership report showing concentrated control of its common stock. CDDS 2.0, LLC now holds 12,733,058 shares, about 41.0% of the company’s 31,059,610 outstanding shares as of April 15, 2026. Damon DeSantis is deemed to beneficially own 12,920,558 shares, or 41.3%, through CDDS and 187,500 presently exercisable stock options held directly. These positions arose from internal transfers from CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis to CDDS for no cash consideration. The reporting group states it currently has no plans involving mergers, asset sales, control changes, or other actions listed in Item 4, while reserving the right to change its intentions.